ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

FTC Seeks Additional Info From Teva, Cephalon Regarding Merger

DOW JONES NEWSWIRES Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) and acquisition target Cephalon Inc. (CEPH) each received a request to provide additional information to the U.S. Federal Trade Commission related to a pending $6.8 billion deal between the firms. Israel-based Teva, which trumped a hostile offer from Valeant Pharmaceuticals International Inc. (VRX) in agreeing to buy Cephalon last month, said it had expected the request. The parties have been cooperating with the FTC staff since shortly after the bid was announced, according to Teva, which said it intends to win clearance "as promptly as possible." Teva on Monday said it continues to expect the deal to be completed in the third quarter, following clearance from U.S. and European regulators, as well as winning approval of Cephalon shareholders. Teva's American depositary shares were recently up 0.4% to $49.35 in after-hours trading. -By John Kell, Dow Jones Newswires; 212-416-2480; john.kell@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
05/27/201611:46:00Correction to Valeant CEO Article on April 21
05/26/201621:00:00Valeant Rejected Joint Takeover Approach From Takeda, TPG
05/26/201607:00:00Valeant Pharmaceuticals Names Sam Eldessouky Senior Vice President...
05/26/201607:00:00Valeant Pharmaceuticals Names Sam Eldessouky Senior Vice President...
05/25/201613:00:00Pharming Reports on Annual General Meeting of Shareholders Pharming's...
05/24/201618:28:00SEC Reviewed Valeant's Use of 'Non-GAAP' Financial Measures...
05/24/201617:09:13Additional Proxy Soliciting Materials (definitive) (defa14a)
05/24/201614:30:00SEC Reviewing Valeant's Use of 'Non-GAAP' Financial Measures
05/24/201614:22:00SEC Reviewing Valeant's Use of 'Non-GAAP' Financial Measures
05/23/201607:00:00Bausch + Lomb Wins Walmart "Supplier of the Year" Award
05/23/201607:00:00Bausch + Lomb Wins Walmart "Supplier of the Year" Award
05/20/201618:20:00Valeant Investor Sequoia Fund to Limit Stakes in a Single Stock
05/20/201616:20:26Current Report Filing (8-k)
05/20/201606:07:08Current Report Filing (8-k)
05/19/201618:00:00Valeant Pharmaceuticals Receives Notice Of Default From Bondholders
05/19/201618:00:00Valeant Pharmaceuticals Receives Notice Of Default From Bondholders
05/18/201615:15:00Valeant Pharmaceuticals To Participate At The UBS Global Healthcare...
05/18/201615:15:00Valeant Pharmaceuticals To Participate At The UBS Global Healthcare...
05/18/201601:00:00Pharming Group: Interim Report on Financial Results for Q1 2016
05/16/201623:20:00Perrigo Updates First-Quarter Loss Figure to Reflect Lower Tax...

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad